Treatment of Duchenne Muscular Dystrophy in Patients Aged 6 Years or Older

Clinical Scenario

This protocol addresses the management of Duchenne muscular dystrophy (DMD) specifically in patients who are 6 years of age or older. Patient age is a key criterion that determines eligibility for approved treatment options in this regimen.

Treatment Approach

For patients meeting the age criterion, treatment involves a histone deacetylase (HDAC) enzyme inhibitor. Complete regimen details, including sequencing, eligibility criteria, and monitoring guidance, are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

Duvyzat (givinostat) — A histone deacetylase (HDAC) enzyme inhibitor approved for the treatment of DMD in patients 6 years of age and older.

View source ↗